½ÃÀ庸°í¼­
»óǰÄÚµå
1453970

Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®

Reconstructed Skin Models Market Forecasts to 2030 - Global Analysis By Type, By Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀåÀº 2023³â¿¡ 3,740¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ Áß CAGR 15.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 9,970¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Àç°Ç ÇǺΠ¸ðµ¨Àº Àΰ£ ÇǺÎÀÇ Æ¯¼º°ú ±â´ÉÀ» ¸ð¹æÇÑ ½ÇÇè½Ç¿¡¼­ Á¦Á¶µÈ ±¸Á¶¹°ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµ¨Àº ÀϹÝÀûÀ¸·Î Ç¥ÇÇ, ÁøÇÇ ¹× °æ¿ì¿¡ µû¶ó¼­´Â ÇÇÇÏÃþÀ» ÀçÇöÇϱâ À§ÇØ ºñ°è ¶Ç´Â ¸ÅÆ®¸¯½º¿¡¼­ Áõ½ÄÇÑ ¼¼Æ÷ ÃþÀ¸·Î ±¸¼ºµË´Ï´Ù. Á¦¾à, È­Àåǰ ¹× ÀÇÇÐ ¿¬±¸¿¡¼­ ÇǺΠ»ý¸®ÇÐ, µ¶¼º Å×½ºÆ®, ½ºÅ²Äɾî Á¦Ç° ¹× Ä¡·á¹ýÀÇ È¿´ÉÀ» ¿¬±¸ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù.

¹Ì±¹ÇǺΰúÇÐȸ°¡ ¹ßÇ¥ÇÑ 2022³â Åë°è¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸ÅÀÏ ¾à 9,500¸íÀÌ ÇÇºÎ¾Ï Áø´ÜÀ» ¹Þ°í ÀÖ´Ù°í ÇÕ´Ï´Ù.

µ¿¹°½ÇÇèÀ» ´ëüÇÒ ¼ö ÀÖ´Â ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

Àç°Ç ÇǺΠ¸ðµ¨Àº µ¿¹° ½ÇÇèÀÇ Çʿ伺À» ´ëüÇÒ ¼ö ÀÖ´Â ÀεµÀûÀ̰í À±¸®ÀûÀÎ ½ÃÇè Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Àΰ£ÀÇ ÇǺΠ»ý¸®¿Í ´Ù¾çÇÑ ¹°Áú¿¡ ´ëÇÑ ¹ÝÀÀÀ» Ãæ½ÇÇÏ°Ô ¸ð¹æÇϰí ÀÖÀ¸¸ç, º¸´Ù Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. µ¿¹° ½ÇÇè¿¡ ´ëÇÑ ±ÔÁ¦°¡ °­È­µÇ°í µ¿¹° º¹Áö¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àç°Ç ÇǺΠ¸ðµ¨ÀÇ Ã¤ÅÃÀÌ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°³¹ß ¹× °ËÁõ¿¡ ¼Ò¿äµÇ´Â ³ôÀº ºñ¿ë

Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ÇǺΠ¸ðµ¨À» ¸¸µé±â À§Çؼ­´Â ÷´Ü ½ÇÇè ½Ã¼³, Ư¼ö Àåºñ, ¼÷·ÃµÈ ÀηÂÀÌ ÇÊ¿äÇÏ¸ç ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ ¸ðµ¨ÀÌ Àΰ£ÀÇ ÇǺΠ»ý¸®¸¦ Á¤È®ÇÏ°Ô ÀçÇöÇϰí ÀÖ´ÂÁö È®ÀÎÇϱâ À§ÇØ ¾ö°ÝÇÑ °ËÁõ Å×½ºÆ®¸¦ ¼öÇàÇÏ´Â °Íµµ ºñ¿ëÀ» Áõ°¡½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ëÀº ¼Ò±Ô¸ð ¿¬±¸ ±â°üÀ̳ª ±â¾÷¿¡°Ô´Â ¾öû³­ ºñ¿ëÀ¸·Î, Àç°Ç ÇǺΠ¸ðµ¨ÀÇ °³¹ß ¹× äÅÃÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±æ°í º¹ÀâÇÑ °ËÁõ °úÁ¤Àº »õ·Î¿î ¸ðµ¨ÀÇ »ó¿ëÈ­¸¦ Áö¿¬½ÃÄÑ º¸±Þ°ú ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¶Á÷°øÇÐÀÇ ±â¼úÀû Áøº¸

¼¼Æ÷ ¹è¾ç ±â¼ú, »ýü Àç·á ¹× 3D ÇÁ¸°ÆÃ ±â¼úÀÇ Çõ½ÅÀ¸·Î º¸´Ù Á¤±³ÇÏ°í »ý¸®ÇÐÀûÀ¸·Î ÀûÇÕÇÑ ÇǺΠ¸ðµ¨ °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº Á¤È®¼º, ±â´É¼º, ÀçÇö¼ºÀÌ Çâ»óµÈ ¸ðµ¨À» ¸¸µé¾î Àΰ£ÀÇ ÇǺΠ»ý¸®¿Í º´¸®¸¦ ´õ Àß ¸ð¹æÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ÀÚµ¿È­ ¹× ÇÏÀ̽º·çDz ½ºÅ©¸®´× ±â¼úÀÇ ¹ßÀüÀ¸·Î À籸¼ºµÈ ÇǺΠ¸ðµ¨ÀÇ ºü¸£°í ºñ¿ë È¿À²ÀûÀÎ Á¦ÀÛ ¹× °ËÁõÀÌ ¿ëÀÌÇØÁ® ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

Ç¥ÁØÈ­ ºÎÁ·

¸ðµ¨ÀÇ °³¹ß, °ËÁõ ¹× »ç¿ë¿¡ ´ëÇÑ º¸ÆíÀûÀ¸·Î ÀÎÁ¤µÈ ÇÁ·ÎÅäÄÝÀ̳ª °¡À̵å¶óÀÎÀÌ ¾ø±â ¶§¹®¿¡ ¸ðµ¨ÀÇ Ç°Áú, ¼º´É ¹× ÀçÇö¼º¿¡ ´ëÇÑ ½ÇÇè½Ç ¹× ¿¬±¸¸¶´Ù Â÷À̰¡ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÒÀÏÄ¡´Â ¿¬±¸ °á°úÀÇ ½Å·Ú¼º°ú ºñ±³ °¡´É¼ºÀ» ÀúÇØÇÏ°í ±ÔÁ¦ Å×½ºÆ® ¹× »ê¾÷ ¿ëµµ¿¡¼­ ÇǺΠÀç°Ç ¸ðµ¨ÀÇ Ã¤ÅÃÀ» ¹æÇØÇÕ´Ï´Ù. ¶ÇÇÑ Ç¥ÁØÈ­µÈ ¹æ¹ý·ÐÀÌ ¾øÀ¸¸é µ¥ÀÌÅÍ ºÒÀÏÄ¡ ¹× À߸øµÈ ÇØ¼®ÀÌ ¹ß»ýÇÒ À§ÇèÀÌ ÀÖÀ¸¸ç, ÀÌ´Â ÀÌÇØ°ü°èÀÚµé »çÀÌ¿¡ ºÒÈ®½Ç¼º°ú ȸÀÇ·ÐÀ» ¾ß±âÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

COVID-19 ÆÒµ¥¹ÍÀº ¿¬±¸ Ȱµ¿°ú °ø±Þ¸Á¿¡ È¥¶õÀ» ÀÏÀ¸ÄÑ Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¿¬±¸¼Ò Æó¼â, ¿©Çà Á¦ÇÑ, »çȸÀû °Å¸®µÎ±â Á¶Ä¡·Î ÀÎÇØ ¸ðµ¨ °³¹ß ¹× °ËÁõ ¿¬±¸°¡ Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ COVID °ü·Ã ¿¬±¸¿¡ ÇÒ´çµÈ Àڱݰú ÀÚ¿øÀÇ °¨¼Ò·Î ÀÎÇØ ½ÃÀåÀÇ ¹ßÀüÀÌ ´õ¿í Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª À̹ø ÆÒµ¥¹ÍÀº ´ëü °Ë»ç ¹æ¹ýÀÇ Á߿伺À» ºÎ°¢½ÃÄ×À¸¸ç, ÇâÈÄ Àç°Ç ÇǺΠ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¿¹Ãø ±â°£ Áß È­Àåǰ °Ë»ç ºÐ¾ß°¡ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

È­Àåǰ Å×½ºÆ® ºÐ¾ß´Â µ¿¹° ½ÇÇè¿¡ ´ëÇÑ ±ÔÁ¦ °­È­¿Í ÀÜÀÎÇÏÁö ¾Ê°í ¾ÈÀüÇÑ È­Àåǰ¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ÇǺΠÀç°Ç ¸ðµ¨ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àç°Ç ÇǺΠ¸ðµ¨Àº µ¿¹° ½ÇÇè ¾øÀ̵µ È­ÀåǰÀÇ ¾ÈÀü¼º, À¯È¿¼º, µ¶¼ºÀ» Æò°¡ÇÒ ¼ö ÀÖ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¸ðµ¨ ±â¼úÀÇ ¹ßÀü°ú À±¸®ÀûÀ̰í Áö¼Ó°¡´ÉÇÑ °üÇà¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó È­Àåǰ Å×½ºÆ®¿¡¼­ ÇǺΠÀç°Ç ¸ðµ¨ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

CRO(Contract Research Organization) ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼öŹ¿¬±¸±â°ü(CRO) ºÎ¹®Àº ¿¹Ãø ±â°£ Áß Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Á¦¾à, È­Àåǰ, ÀÇ·á±â±â ±â¾÷ÀÌ ¿¬±¸ ¹× ½ÃÇè Ȱµ¿À» CRO¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. À̵é Á¶Á÷Àº Àç°Ç ÇǺΠ¸ðµ¨À» ÀÌ¿ëÇÑ ¾ÈÀü¼º ¹× À¯È¿¼º ½ÃÇèÀ» Æ÷ÇÔÇÑ ÀüÀÓ»ó½ÃÇè ¼öÇàÀ» Àü¹®À¸·Î Çϸç, Á¦Ç° °³¹ß ¹× ±ÔÁ¦ Áؼö¸¦ À§ÇÑ ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

°¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª :

ºÏ¹Ì´Â ÇコÄÉ¾î ¹× Á¦¾à »ê¾÷ÀÇ È£Á¶¿Í Ȱ¹ßÇÑ R&D Ȱµ¿À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ±ÔÁ¦ ±âÁØÀÌ ¾ö°ÝÇÏ¿© Àç°Ç ÇǺΠ¸ðµ¨°ú °°Àº ½Å·ÚÇÒ ¼ö ÀÖ°í Á¤È®ÇÑ °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È­Àåǰ ¹× ÀǾàǰ¿¡ ´ëÇÑ À±¸®ÀûÀ̰í È¿°úÀûÀÎ Å×½ºÆ® ¹æ¹ýÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ºÏ¹Ì ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¿¹Ãø ±â°£ Áß À¯·´Àº Àç°Ç¿ë ÇǺΠ¸ðµ¨ ½ÃÀå¿¡¼­ Å« ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´Àº Àß È®¸³µÈ Á¦¾à ¹× È­Àåǰ »ê¾÷À» ÀÚ¶ûÇϸç, ¾ÈÀü¼º°ú À¯È¿¼º Å×½ºÆ®¸¦ ¿ì¼±½ÃÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁذú °áÇյǾî ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í À±¸®ÀûÀ̰í Á¤È®ÇÑ Å×½ºÆ®¸¦ À§ÇÑ Àç°Ç ÇǺΠ¸ðµ¨ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεé·Î ÀÎÇØ À¯·´Àº Àç°Ç ÇǺΠ¸ðµ¨ÀÇ ÁÖ¿ä ¼ºÀå ½ÃÀåÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ Á¦°ø:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. :

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(ÃÖ´ë 3°³»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤Ä¡, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¿ªÀû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå : À¯Çüº°

  • Ç¥ÇÇ ÇǺΠ¸ðµ¨
  • ÁøÇÇ ¸ðµ¨
  • 3D Àç°Ç ÇǺΠ¸ðµ¨

Á¦6Àå ¼¼°èÀÇ Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå : ¿ëµµº°

  • È­Àåǰ ½ÃÇè
    • ÇǺΠÀڱؼº ½ÃÇè
    • ÇǺΠ°¨ÀÛ¼º ½ÃÇè
  • È­Çй°Áú ¹× µ¶¼º ½ÃÇè
  • ±âŸ ¿ëµµ

Á¦7Àå ¼¼°èÀÇ Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)
  • È­Àåǰ ȸ»ç
  • Á¦¾àȸ»ç ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ȸ»ç
  • ¿¬±¸±â°ü°ú Çмú°è
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ¼¼°èÀÇ Àç°Ç ÇǺΠ¸ðµ¨ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕº´»ç¾÷
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç°ÀÇ ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦10Àå ±â¾÷ °³¿ä

  • AIVITA Biomedical
  • Biopredic International
  • CellSystems
  • CellTechMed GmbH
  • Genoskin
  • LabSkin Creations
  • L'Oreal S.A.
  • MatTek Corporation
  • OrSkin
  • QGel SA
  • SkinEthic Laboratories
  • StratiCELL
  • Tissue Regeneration Sciences, Inc.
  • VITROCELL Systems GmbH
KSA 24.04.30

According to Stratistics MRC, the Global Reconstructed Skin Models Market is accounted for $37.4 million in 2023 and is expected to reach $99.7 million by 2030 growing at a CAGR of 15.0% during the forecast period. Reconstructed skin models are laboratory-produced structures that mimic the properties and functions of human skin. These models typically consist of layers of cells grown on scaffolds or matrices, replicating the epidermis, dermis, and sometimes the subcutaneous layer. They are used in pharmaceutical, cosmetic, and medical research to study skin physiology, toxicity testing, and the efficacy of skincare products and treatments.

According to 2022 statistics published by American Academy of Dermatology, it was reported that approximately 9,500 people are diagnosed with skin cancer every day in the U.S.

Market Dynamics:

Driver:

Growing demand for alternatives to animal testing

Reconstructed skin models offer a humane and ethical approach to testing, replacing the need for animal experimentation. Additionally, they provide more accurate and reliable results, as they closely mimic human skin physiology and response to various substances. With increasing regulatory restrictions on animal testing and rising awareness of animal welfare concerns, the adoption of reconstructed skin models is expected to rise significantly.

Restraint:

High cost of development and validation

Creating accurate and reliable skin models requires sophisticated laboratory facilities, specialized equipment, and skilled personnel, which entail substantial investments. Additionally, conducting rigorous validation studies to ensure the models accurately replicate human skin physiology further adds to the cost. These expenses can be prohibitive for smaller research institutions and companies, limiting their ability to develop and adopt reconstructed skin models. Moreover, the lengthy and complex validation process may delay the commercialization of new models, hindering their widespread adoption and market growth.

Opportunity:

Technological advancements in tissue engineering

Innovations in cell culture techniques, biomaterials, and 3D printing technologies enable the development of more sophisticated and physiologically relevant skin models. These advancements allow researchers to create models with improved accuracy, functionality, and reproducibility, better mimicking human skin physiology and pathology. Additionally, advancements in automation and high-throughput screening techniques facilitate the rapid and cost-effective generation and validation of reconstructed skin models, driving market growth.

Threat:

Lack of standardization

The absence of universally accepted protocols and guidelines for model development, validation, and usage results in variability in model quality, performance, and reproducibility across different laboratories and research studies. This inconsistency undermines the reliability and comparability of research findings, hindering the adoption of reconstructed skin models in regulatory testing and industrial applications. Moreover, without standardized methodologies, there is a risk of data discrepancies and misinterpretation, leading to uncertainty and skepticism among stakeholders.

Covid-19 Impact:

The COVID-19 pandemic has impacted the reconstructed skin models market by disrupting research activities and supply chains. Laboratory closures, travel restrictions, and social distancing measures have led to delays in model development and validation studies. Additionally, reduced funding and resources allocated to non-COVID-related research have further slowed progress in the market. However, the pandemic has also highlighted the importance of alternative testing methods, potentially driving future demand for reconstructed skin models.

The cosmetics testing segment is expected to be the largest during the forecast period

The cosmetics testing segment is projected to lead the reconstructed skin models market during the forecast period due to increasing regulatory restrictions on animal testing and rising consumer demand for cruelty-free and safe cosmetic products. Reconstructed skin models offer a reliable alternative for assessing the safety, efficacy, and toxicity of cosmetics without the need for animal testing. Additionally, advancements in model technology and growing awareness of ethical and sustainable practices further drive the adoption of reconstructed skin models in cosmetics testing.

The contract research organizations (CROs) segment is expected to have the highest CAGR during the forecast period

The contract research organizations (CROs) segment is anticipated to achieve the highest growth rate in the reconstructed skin models market during the forecast period. This growth can be attributed to the increasing outsourcing of research and testing activities by pharmaceutical, cosmetic, and medical device companies to CROs. These organizations specialize in conducting preclinical studies, including safety and efficacy testing using reconstructed skin models, offering cost-effective and efficient solutions for product development and regulatory compliance.

Region with largest share:

During the forecast period, the North American region is poised to lead the reconstructive skin models market owing to its robust healthcare and pharmaceutical industries and high levels of research and development activities. The region has stringent regulatory standards, driving the demand for reliable and accurate testing methods such as reconstructed skin models. Additionally, increasing awareness about the importance of ethical and effective testing methods for cosmetic and pharmaceutical products further contributes to the market's growth in North America.

Region with highest CAGR:

During the forecast period, Europe is expected to experience significant growth in the reconstructive skin models market. Europe boasts a well-established pharmaceutical and cosmetic industry, coupled with stringent regulatory standards that prioritize safety and efficacy testing. Additionally, increasing investments in research and development, along with growing awareness about the benefits of reconstructed skin models for ethical and accurate testing, are driving market growth in the region. These factors position Europe as a key growth market for reconstructive skin models.

Key players in the market

Some of the key players in Reconstructed Skin Models Market include AIVITA Biomedical, Biopredic International, CellSystems, CellTechMed GmbH, Genoskin, LabSkin Creations, L'Oreal S.A. , MatTek Corporation, OrSkin, QGel SA, SkinEthic Laboratories, StratiCELL, Tissue Regeneration Sciences, Inc. and VITROCELL Systems GmbH.

Key Developments:

In June 2023, L'Oreal announced a partnership with the University of California (UC) Berkeley's biotech incubator Bakar Labs. The collaboration opens up avenues for Bakar Labs' incubated startups to benefit from and gain access to L'Oreal's 3D reconstructed skin models, at no cost.

In March 2023, Chanel Research has just made a strategic leap forward to accelerate its knowledge of skin pigment spots, a major aesthetic concern among aging populations, particularly in Asia. In partnership with LabSkin Creations, the luxury giant has successfully used 3D bioprinting techniques to create reconstructed human skin on which a dark spot can appear.

Types Covered:

  • Epidermal Skin Models
  • Dermal Skin Models
  • 3D Reconstructed Skin Models

Applications Covered:

  • Cosmetics Testing
  • Chemicals and Toxicology Testing
  • Other Applications

End Users Covered:

  • Contract Research Organizations (CROs)
  • Cosmetic Companies
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes and Academia
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Reconstructed Skin Models Market, By Type

  • 5.1 Introduction
  • 5.2 Epidermal Skin Models
  • 5.3 Dermal Skin Models
  • 5.4 3D Reconstructed Skin Models

6 Global Reconstructed Skin Models Market, By Application

  • 6.1 Introduction
  • 6.2 Cosmetics Testing
    • 6.2.1 Skin Irritation Test
    • 6.2.2 Skin Sensitization Test
  • 6.3 Chemicals and Toxicology Testing
  • 6.4 Other Applications

7 Global Reconstructed Skin Models Market, By End User

  • 7.1 Introduction
  • 7.2 Contract Research Organizations (CROs)
  • 7.3 Cosmetic Companies
  • 7.4 Pharmaceutical and Biotechnology Companies
  • 7.5 Research Institutes and Academia
  • 7.6 Other End Users

8 Global Reconstructed Skin Models Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AIVITA Biomedical
  • 10.2 Biopredic International
  • 10.3 CellSystems
  • 10.4 CellTechMed GmbH
  • 10.5 Genoskin
  • 10.6 LabSkin Creations
  • 10.7 L'Oreal S.A.
  • 10.8 MatTek Corporation
  • 10.9 OrSkin
  • 10.10 QGel SA
  • 10.11 SkinEthic Laboratories
  • 10.12 StratiCELL
  • 10.13 Tissue Regeneration Sciences, Inc.
  • 10.14 VITROCELL Systems GmbH
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦